TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22406709

Group type: EXPERIMENTAL
Intervention: Brush-covered Navi Tip FX (Group I)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Side-vented needle (Group II)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Single-beveled needle (Group III)
Number of subjects: 30
Study: 19023632

Group type: EXPERIMENTAL
Intervention: FDG-PET
Number of subjects: 41
Study: 17523581

Group type: EXPERIMENTAL
Intervention: Multiple KPT group (two addiction counseling sessions followed by two KPT sessions)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Single KPT group (two addiction counseling sessions with no additional ketamine therapy)
Number of subjects: 59
Study: 15448531

Group type: EXPERIMENTAL
Intervention: Basal group (12-ml/h basal rate, 0.05-ml patient-controlled bolus dose)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Basal-bolus group (8-ml/h basal rate, 4-ml bolus dose)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bolus group (0.3-ml/h basal rate, 9.9-ml bolus dose)
Number of subjects: 30

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 30
Study: 11850998

Group type: EXPERIMENTAL
Intervention: Noninvasive positive pressure ventilation (NPPV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NPPV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long term NPPV
Number of subjects: 0
Study: 9718120

Group type: COMPARATOR
Intervention: AZT monotherapy
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: AZT + ddC (Zalcitabine)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: AZT + ddI (Didanosine)
Number of subjects: 42
Study: 7491174

Group type: EXPERIMENTAL
Intervention: SPET imaging
Number of subjects: 110

Group type: COMPARATOR
Intervention: Planar imaging
Number of subjects: 110

Group type: COMPARATOR
Intervention: Both imaging tests
Number of subjects: 110
Study: 2566058

Group type: EXPERIMENTAL
Intervention: Visual appearance and dipstick testing for nitrite and leucocyte esterase
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Various screening tests (visual appearance, microscopy, dipstick for nitrite, leucocyte esterase, protein, and blood, dipstick for nitrite and organisms)
Number of subjects: 418
Study: 333862

Group type: COMPARATOR
Intervention: Biphasic hormone combination (Cyclacur) with 2 mg estradiol valerianate for 11 days, followed by 2 mg estradiol valerianate plus 0.5 mg dl‐norgestrel for 10 days, and a 7-day medication-free period.
Number of subjects: 20
Study: 31627408

Group type: EXPERIMENTAL
Intervention: Circulating copper concentrations
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Copper/zinc ratio
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Plasma copper
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Zinc
Number of subjects: 139
Study: 27353750

Group type: EXPERIMENTAL
Intervention: Daily disposable hydrogel contact lenses worn by CLIDE
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Daily disposable hydrogel contact lenses worn by NO-CLIDE
Number of subjects: 60
Study: 26032239

Group type: EXPERIMENTAL
Intervention: Trebananib and Paclitaxel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paclitaxel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other Chemotherapeutic Agents
Number of subjects: 0
Study: 23377328

Group type: EXPERIMENTAL
Intervention: Topical product containing 0.5% ellagic acid and 0.1% salicylic acid
Number of subjects: 54

Group type: COMPARATOR
Intervention: 4% hydroquinone (HQ)
Number of subjects: 54
Study: 21187200

Group type: EXPERIMENTAL
Intervention: verum treatment (acupoint ST-34 stimulation)
Number of subjects: 60

Group type: COMPARATOR
Intervention: control treatment (nonacupoint stimulation)
Number of subjects: 60
Study: 19133707

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 microg/kg plus 2% prilocaine 3 mg/kg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Lornoxicam 8 mg plus 2% prilocaine 3 mg/kg
Number of subjects: 75

Group type: COMPARATOR
Intervention: 2% prilocaine 3 mg/kg
Number of subjects: 75
Study: 17382827

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 1721

Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 1721
Study: 15499141

Group type: EXPERIMENTAL
Intervention: Caffeine citrate 20 mg/kg/day
Number of subjects: 234

Group type: COMPARATOR
Intervention: Caffeine citrate 5 mg/kg/day
Number of subjects: 234
Study: 11226796

Group type: EXPERIMENTAL
Intervention: Intrastromal corneal ring segments (ICRS) of various thicknesses (0.25, 0.30, 0.35, 0.40, or 0.45 mm)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 107
Study: 9659527

Group type: EXPERIMENTAL
Intervention: Standard gas mixture
Number of subjects: 20

Group type: COMPARATOR
Intervention: High-oxygen gas mixture
Number of subjects: 20

Group type: COMPARATOR
Intervention: Long protocol (30 min waiting time)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Short protocol (5 min waiting time)
Number of subjects: 20
Study: 7718142

Group type: EXPERIMENTAL
Intervention: Phyllanthus urinaria
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Phyllanthus amarus
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Phyllanthus niruri
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 88
Study: 2729944

Group type: EXPERIMENTAL
Intervention: Cefmetazole sodium (0.375 g)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cefmetazole sodium (0.750 g)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cefmetazole sodium (1 g)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cefmetazole sodium (2 g)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (sterile saline)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cefmetazole sodium (0.375 g to 2 g)
Number of subjects: 40
Study: 30976787

Group type: EXPERIMENTAL
Intervention: Uninterrupted edoxaban 60 mg (30 mg for dose reduction)
Number of subjects: 632

Group type: COMPARATOR
Intervention: Vitamin K antagonists (VKAs)
Number of subjects: 632

Group type: EXPERIMENTAL
Intervention: Uninterrupted edoxaban
Number of subjects: 632
Study: 29273578

Group type: EXPERIMENTAL
Intervention: Dasiglucagon 0.1 mg
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Dasiglucagon 0.3 mg
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Dasiglucagon 0.6 mg
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Dasiglucagon 1.0 mg
Number of subjects: 58

Group type: COMPARATOR
Intervention: GlucaGen 0.5 mg
Number of subjects: 58

Group type: COMPARATOR
Intervention: GlucaGen 1.0 mg
Number of subjects: 58
Study: 26727369

Group type: EXPERIMENTAL
Intervention: Integrated Management of Neonatal and Childhood Illnesses (IMNCI) program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IMNCI program
Number of subjects: 0
Study: 24196558

Group type: EXPERIMENTAL
Intervention: Duodenal-jejunal bypass liner (DJBL)
Number of subjects: 79
Study: 22366974

Group type: EXPERIMENTAL
Intervention: Femur-first technique (group F)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Tibia-first technique (group T)
Number of subjects: 116
Study: 19397661

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Polarization-sensitive OCT (PS-OCT)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: OCT and PS-OCT
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: OCT
Number of subjects: 104
Study: 17451280

Group type: EXPERIMENTAL
Intervention: lormetazepam 0.5mg + SHT
Number of subjects: 30

Group type: COMPARATOR
Intervention: SHT alone
Number of subjects: 30
Study: 15170701

Group type: EXPERIMENTAL
Intervention: Radial access
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Femoral 6 Fr with AngioSeal closure (F+C)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Femoral 4 Fr without closure
Number of subjects: 75
Study: 11136281

Group type: EXPERIMENTAL
Intervention: OMC (omeprazole, metronidazole, clarithromycin)
Number of subjects: 892

Group type: EXPERIMENTAL
Intervention: OFC (omeprazole, furazolidone, clarithromycin)
Number of subjects: 892

Group type: EXPERIMENTAL
Intervention: OFA (omeprazole, furazolidone, amoxicillin)
Number of subjects: 892

Group type: EXPERIMENTAL
Intervention: BFC (colloidal bismuth subcitrate, furazolidone, clarithromycin)
Number of subjects: 892
Study: 10399513

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Cuffed Oropharyngeal Airway (COPA)
Number of subjects: 80
Study: 7527421

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) administered at the same time as buserelin-HMG
Number of subjects: 0

Group type: COMPARATOR
Intervention: No growth hormone (GH) administered
Number of subjects: 0
Study: 2537003

Group type: EXPERIMENTAL
Intervention: Guar gum treatment
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Guar gum treatment (after switching from placebo)
Number of subjects: 39
Study: 31646416

Group type: EXPERIMENTAL
Intervention: Self-report using EQ-5D-5L
Number of subjects: 726

Group type: COMPARATOR
Intervention: Proxy-report using EQ-5D-5L (relatives)
Number of subjects: 726

Group type: COMPARATOR
Intervention: Proxy-report using EQ-5D-5L (staff)
Number of subjects: 726

Group type: EXPERIMENTAL
Intervention: DEMQOL, EQ-5D-5L, QOL-AD, QUALID measures
Number of subjects: 726
Study: 30646929

Group type: EXPERIMENTAL
Intervention: DHEA treatment for 4-12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment for 4-12 weeks
Number of subjects: 0
Study: 28556584

Group type: EXPERIMENTAL
Intervention: High doses of prednisone (0.8-1.0 mg/kg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Medium doses of prednisone (0.5-0.6 mg/kg/day)
Number of subjects: 40
Study: 26212603

Group type: EXPERIMENTAL
Intervention: Usual care plus assessment with the Hyperemesis Impact of Symptoms questionnaire and a tailored care plan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 23312689

Group type: EXPERIMENTAL
Intervention: Liquid formulation of levothyroxine (group 1)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Tablet formulation of levothyroxine (group 2)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both groups (1 and 2)
Number of subjects: 42
Study: 20080830

Group type: EXPERIMENTAL
Intervention: Palonosetron (0.25 mg) + Dexamethasone (8 mg) on day 1
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo on days 2 and 3
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Dexamethasone (4 mg b.i.d.) on days 2 and 3
Number of subjects: 300
Study: 18389745

Group type: EXPERIMENTAL
Intervention: 0.9% saline alone (Group A, n=16)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: lactated Ringer's solution alone (Group B, n=16)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 0.9% saline and Ringer's solution, 1:1 ratio (Group C, n=15)
Number of subjects: 47
Study: 16847790

Group type: EXPERIMENTAL
Intervention: C-Leg microprocessor-controlled knee
Number of subjects: 8

Group type: COMPARATOR
Intervention: Mauch SNS knee
Number of subjects: 8
Study: 12477770

Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (normolipidaemic)
Number of subjects: 19
Study: 11022927

Group type: EXPERIMENTAL
Intervention: Adoptive immunotherapy (n=76)
Number of subjects: 150

Group type: COMPARATOR
Intervention: No adjuvant treatment (control group, n=74)
Number of subjects: 150
Study: 8792046

Group type: EXPERIMENTAL
Intervention: Tension night splint (TNS) in addition to standard treatment (anti-inflammatory medication, Viscoheel sofspot heel cushion, stretching program)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (standard treatment: anti-inflammatory medication, Viscoheel sofspot heel cushion, stretching program)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group after crossover to TNS
Number of subjects: 32
Study: 8315648

Group type: EXPERIMENTAL
Intervention: Instructional audiotape
Number of subjects: 54

Group type: COMPARATOR
Intervention: No tape (control group)
Number of subjects: 54
Study: 3736637

Group type: EXPERIMENTAL
Intervention: Treatment of hyperprolactinemia
Number of subjects: 32

Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 32
Study: 29519882

Group type: EXPERIMENTAL
Intervention: Intensive treatment group
Number of subjects: 547

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Intensive treatment group (after transfer of 25 participants)
Number of subjects: 547
Study: 25230304

Group type: EXPERIMENTAL
Intervention: Intracoronary anisodamine (1 mg/5 ml) and diltiazem (2 mg/5 ml)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Intracoronary anisodamine and diltiazem
Number of subjects: 108

Group type: COMPARATOR
Intervention: Saline (5 ml) and diltiazem (2 mg/5 ml)
Number of subjects: 108
Study: 22614887

Group type: EXPERIMENTAL
Intervention: D-dimer added to conventional mortality risk factors
Number of subjects: 1946

Group type: COMPARATOR
Intervention: Reference model without D-dimer
Number of subjects: 1946
Study: 20124139

Group type: EXPERIMENTAL
Intervention: Metformin XR, 2000 mg once daily
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 18841263

Group type: EXPERIMENTAL
Intervention: rosiglitazone (4 mg/day to 8 mg/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: metformin (500 mg/day to 2000 mg/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: glyburide (5 mg/day to 20 mg/day)
Number of subjects: 100
Study: 15932703

Group type: EXPERIMENTAL
Intervention: Tongxinluo capsule
Number of subjects: 112

Group type: COMPARATOR
Intervention: Routine drug treatment
Number of subjects: 112
Study: 11834429

Group type: EXPERIMENTAL
Intervention: Fasting with GH receptor blockade (pegvisomant)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Fasting without GH receptor blockade
Number of subjects: 10
Study: 10612300

Group type: EXPERIMENTAL
Intervention: Intradermal vaccination (5 mcg every 2 weeks for 8 doses, plus 1 i.m. dose at month 12)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Intramuscular vaccination (20 mcg for 4 doses at months 0, 1, 2, and 12)
Number of subjects: 32
Study: 7821102

Group type: EXPERIMENTAL
Intervention: 250 mg erythromycin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1000 mg erythromycin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2239724

Group type: EXPERIMENTAL
Intervention: Primary ventricular fibrillation (VF)
Number of subjects: 5839

Group type: COMPARATOR
Intervention: Reference group (no primary VF)
Number of subjects: 5839
Study: 364258

Group type: EXPERIMENTAL
Intervention: Australian version of the Feingold elimination diet
Number of subjects: 16
Study: 31289971

Group type: EXPERIMENTAL
Intervention: Tooth whitening with a photo-activated whitening gel
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 60
Study: 31744060

Group type: EXPERIMENTAL
Intervention: Eggplant powder (1.2 g/day; 2.3 mg of ACh/day) for 12 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 100
Study: 28915283

Group type: EXPERIMENTAL
Intervention: Multi-modal facial serum containing HA, Proxylane (C‐Xyloside), purple rice extract, and dipotassium glycyrrhizate
Number of subjects: 59
Study: 25543296

Group type: COMPARATOR
Intervention: Chlorhexidine varnish 2%
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: c-PACT (curcumin at 1.5 mg.mL(‐1) with blue LED light)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo varnish
Number of subjects: 35
Study: 23112214

Group type: EXPERIMENTAL
Intervention: Balanced starch (HES, 130/0.4, 6%) solution
Number of subjects: 50

Group type: COMPARATOR
Intervention: Balanced crystalloid solution
Number of subjects: 50
Study: 20924633

Group type: EXPERIMENTAL
Intervention: Daily dose of G-CSF (lenograstim, 100 μg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: G-CSF (100 μg) administered every other day
Number of subjects: 30
Study: 19183141

Group type: EXPERIMENTAL
Intervention: 20 mg of paroxetine (Paxil)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Alcohol (mean blood alcohol concentration of 0.10%)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo pill
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo drink (no alcohol)
Number of subjects: 56
Study: 16995813

Group type: EXPERIMENTAL
Intervention: Risedronate (5 mg/day, orally)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15316642

Group type: EXPERIMENTAL
Intervention: 3 mg midazolam
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: 0.1 mg fentanyl
Number of subjects: 174

Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 174
Study: 11564852

Group type: EXPERIMENTAL
Intervention: Community-based participatory research partnership
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Facilitating factors identified by Board members
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ongoing challenges identified by Board members
Number of subjects: 0
Study: 9292360

Group type: EXPERIMENTAL
Intervention: HIV awareness training programme
Number of subjects: 65

Group type: COMPARATOR
Intervention: No training (Control)
Number of subjects: 65
Study: 8487239

Group type: EXPERIMENTAL
Intervention: Sequential therapy with MPA 5.0 mg for 12 days of each 25-day cycle plus CEE 0.625 mg daily
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Continuous therapy with MPA 2.5 mg daily for 12 treatment cycles plus CEE 0.625 mg daily
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Continuous therapy with MPA 5.0 mg daily for 12 treatment cycles plus CEE 0.625 mg daily
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: All treatment groups (sequential and continuous)
Number of subjects: 36
Study: 3302998

Group type: EXPERIMENTAL
Intervention: Piroxicam, 20 mg daily, orally for 10 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo, orally for 10 days
Number of subjects: 40
Study: 29227377

Group type: EXPERIMENTAL
Intervention: Chlorthalidone 12.5 mg and Amiloride 2.5 mg once a day
Number of subjects: 730

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 730
Study: 27996320

Group type: COMPARATOR
Intervention: CL alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CL+snack
Number of subjects: 12
Study: 24548581

Group type: EXPERIMENTAL
Intervention: Parental concern scores (CFQ)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Parental responsibility scores (CFQ)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Changes in CFQ subscale scores
Number of subjects: 77
Study: 22237061

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (200,000 IU/week for 3 weeks)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 20691067

Group type: EXPERIMENTAL
Intervention: Staying healthy at work
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 0
Study: 17888078

Group type: EXPERIMENTAL
Intervention: Intravenous lacosamide (60-min infusions)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intravenous lacosamide (30-min infusions)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral lacosamide (control)
Number of subjects: 60
Study: 16826019

Group type: EXPERIMENTAL
Intervention: Moderate to vigorous physical activity (MVPA)
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Vigorous physical activity (VPA)
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Lesson context by field site
Number of subjects: 431

Group type: COMPARATOR
Intervention: Coed vs girls-only classes
Number of subjects: 431

Group type: COMPARATOR
Intervention: Outdoor lessons vs indoor lessons
Number of subjects: 431
Study: 12538372

Group type: EXPERIMENTAL
Intervention: Parecoxib sodium 20 mg bd i.v.
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Parecoxib sodium 40 mg bd i.v.
Number of subjects: 195

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study: 11515622

Group type: EXPERIMENTAL
Intervention: One-week treatment with lansoprazole (30 mg bid), clarithromycin (500 mg bid), and amoxycillin (1 g bid)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Two-week treatment with lansoprazole (30 mg bid), clarithromycin (500 mg bid), and amoxycillin (1 g bid)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Helicobacter pylori cured patients
Number of subjects: 71

Group type: COMPARATOR
Intervention: Helicobacter pylori persisting infection
Number of subjects: 71
Study: 8890678

Group type: EXPERIMENTAL
Intervention: Diazepam (intravenous doses)
Number of subjects: 47
Study: 1900687

Group type: EXPERIMENTAL
Intervention: ACNU + Futraful (FT)
Number of subjects: 2456

Group type: EXPERIMENTAL
Intervention: MMC + FT
Number of subjects: 2456

Group type: EXPERIMENTAL
Intervention: ADM + FT
Number of subjects: 2456

Group type: COMPARATOR
Intervention: FT alone
Number of subjects: 2456
Study: 6225313

Group type: EXPERIMENTAL
Intervention: Zimelidine (225 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Desipramine (150 mg)
Number of subjects: 24
Study: 31425397

Group type: EXPERIMENTAL
Intervention: Data to Care (D2C) model implementation
Number of subjects: 3
Study: 29551533

Group type: EXPERIMENTAL
Intervention: SQ tree SLIT-tablet (7 DU)
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: SQ tree SLIT-tablet (all doses)
Number of subjects: 637

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 637
Study: 26951571

Group type: EXPERIMENTAL
Intervention: 3 months of directly observed once‐weekly rifapentine (maximum dose, 900 mg) plus isoniazid (maximum dose, 900 mg) (3HP‐DOT)
Number of subjects: 6232

Group type: COMPARATOR
Intervention: 9 months of daily self‐administered isoniazid (maximum dose, 300 mg; 9H‐SAT)
Number of subjects: 6232
Study: 25011612

Group type: EXPERIMENTAL
Intervention: Exercise referral scheme to a group physical activity program at sports facilities, duration not specified.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Information about physical activity benefits and ways to increase it safely (Control Group).
Number of subjects: 0
Study: 21602517

Group type: EXPERIMENTAL
Intervention: Coadministration of ketoconazole (a potent CYP3A4 inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coadministration of erythromycin (a moderate CYP3A4 inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coadministration of rifampin (a potent CYP3A4 inducer)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ruxolitinib alone and in combination with ketoconazole, erythromycin, or rifampin
Number of subjects: 0
Study: 19105762

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 0